EQUTY INVESTMENT (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|---|
Dec. 18, 2018 |
Sep. 30, 2019 |
Sep. 30, 2018 |
Sep. 30, 2019 |
Sep. 30, 2018 |
May 06, 2019 |
|
| SHARE OF NET LOSSES OF EQUITY METHOD INVESTEE | $ (196,000) | $ (345,000) | ||||
| Equity Method Goodwill | 5,000,000 | 5,000,000 | ||||
| ILiAD [Member] | ||||||
| Advisory and legal expenses | 41,000 | |||||
| ILiAD [Member] | Maximum [Member] | ||||||
| Investment | $ 5,000,000 | |||||
| ILiAD [Member] | Tranche One [Member] | ||||||
| Initial investment | $ 2,500,000 | |||||
| Description for the terms of allowed-to-proceed notice under aggrement | May 2, 2019 that it had received an "allowed to proceed" notice from the FDA permitting ILiAD to advance to the Phase 2b clinical study of its BP2E1 vaccine. ILiAD elected to permit its Class C investors (including the Company) to bifurcate their tranche 2 commitment such that 40% would be currently due ($1,000,000 paid by the Company on May 6, 2019) and 60% (additional $1,500,000 investment by the Company) would be due when ILiAD received satisfactory safety data from the clinical study. On August 9, 2019, ILiAD notified the Company that the FDA has allowed Phase 2b to proceed to full enrollment based on satisfactory safety data from the first phase of the clinical study which triggered the Company's additional $1,500,000 investment. At September 30, 2019, the Company owned approximately 10.4% of the outstanding units of ILiAD (on a non-fully diluted basis). | |||||
| ILiAD [Member] | Tranche Two [Member] | ||||||
| Initial investment | $ 2,500,000 | $ 2,500,000 | ||||
| ILiAD [Member] | Warrant [Member] | ||||||
| Units purchase | 366,666 | 366,666 | ||||
| Price per unit | $ 2.75 | $ 2.75 | ||||
| ILiAD [Member] | Class C units [Member] | ||||||
| Ownership percentage | 8.40% | |||||
| ILiAD [Member] | Class C units [Member] | Maximum [Member] | ||||||
| Investment | $ 16,200,000 | |||||
| ILiAD [Member] | Class C units [Member] | Tranche One [Member] | ||||||
| Units purchase | 1,111,111 | 1,111,111 | ||||
| Price per unit | $ 2.25 | $ 2.25 | ||||
| ILiAD [Member] | Class C units [Member] | Tranche Two [Member] | ||||||
| Units purchase | 943,396 | |||||
| Price per unit | $ 2.65 | |||||
| Warrants to purchase units | 311,320 | |||||
| Exercise price | $ 3.50 | |||||